CN1511958A - System of T cell surface antigen peptide screening human tissue compatibility antigen (HLA) and its application in producing MHC-antigen peptide polymer - Google Patents
System of T cell surface antigen peptide screening human tissue compatibility antigen (HLA) and its application in producing MHC-antigen peptide polymer Download PDFInfo
- Publication number
- CN1511958A CN1511958A CNA021599742A CN02159974A CN1511958A CN 1511958 A CN1511958 A CN 1511958A CN A021599742 A CNA021599742 A CN A021599742A CN 02159974 A CN02159974 A CN 02159974A CN 1511958 A CN1511958 A CN 1511958A
- Authority
- CN
- China
- Prior art keywords
- peptide
- antigen
- cell
- hla
- phage
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 63
- 239000000427 antigen Substances 0.000 title claims abstract description 44
- 102000036639 antigens Human genes 0.000 title claims abstract description 40
- 108091007433 antigens Proteins 0.000 title claims abstract description 40
- 210000001744 T-lymphocyte Anatomy 0.000 title claims abstract description 25
- 238000012216 screening Methods 0.000 title claims abstract description 18
- 229920000642 polymer Polymers 0.000 title claims abstract description 14
- 101710160107 Outer membrane protein A Proteins 0.000 title claims description 8
- 238000002360 preparation method Methods 0.000 claims abstract description 19
- 238000002054 transplantation Methods 0.000 claims abstract description 8
- 210000004027 cell Anatomy 0.000 claims description 27
- 238000000034 method Methods 0.000 claims description 17
- 239000003018 immunosuppressive agent Substances 0.000 claims description 12
- 241000894006 Bacteria Species 0.000 claims description 7
- 230000000968 intestinal effect Effects 0.000 claims description 7
- 210000000056 organ Anatomy 0.000 claims description 7
- 108090000623 proteins and genes Proteins 0.000 claims description 7
- 238000005406 washing Methods 0.000 claims description 7
- 238000005516 engineering process Methods 0.000 claims description 6
- 239000002299 complementary DNA Substances 0.000 claims description 5
- 238000012360 testing method Methods 0.000 claims description 5
- 241000588724 Escherichia coli Species 0.000 claims description 3
- 238000010367 cloning Methods 0.000 claims description 3
- 230000002950 deficient Effects 0.000 claims description 3
- 238000002823 phage display Methods 0.000 claims description 3
- 239000013612 plasmid Substances 0.000 claims description 3
- 238000012163 sequencing technique Methods 0.000 claims description 3
- 108090000565 Capsid Proteins Proteins 0.000 claims description 2
- 102100023321 Ceruloplasmin Human genes 0.000 claims description 2
- 230000005867 T cell response Effects 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 238000010828 elution Methods 0.000 claims description 2
- 239000012645 endogenous antigen Substances 0.000 claims description 2
- 108010091938 HLA-B7 Antigen Proteins 0.000 claims 1
- 239000003480 eluent Substances 0.000 claims 1
- 230000004768 organ dysfunction Effects 0.000 claims 1
- 238000011895 specific detection Methods 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 abstract description 7
- 230000001900 immune effect Effects 0.000 abstract description 2
- 239000003112 inhibitor Substances 0.000 abstract 1
- 238000012544 monitoring process Methods 0.000 abstract 1
- 238000001514 detection method Methods 0.000 description 7
- 238000013016 damping Methods 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 230000005859 cell recognition Effects 0.000 description 3
- 238000002523 gelfiltration Methods 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 150000008065 acid anhydrides Chemical class 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 101710175243 Major antigen Proteins 0.000 description 1
- 108091030071 RNAI Proteins 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000001815 biotherapy Methods 0.000 description 1
- 231100000313 clinical toxicology Toxicity 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 238000009775 high-speed stirring Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000011337 individualized treatment Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000036647 reaction Effects 0.000 description 1
- 238000004153 renaturation Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 101150095542 tap gene Proteins 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The present invention belongs to the field of biomedicine preparation, is T-cell surface antigen peptide for screening human histocompatibility antigen and its application in preparing MHC-antigen peptide polymer. The MHC-peptide tetramer prepared with the histoantigen peptide may be used in monitoring homoplastic transplantation rejection reaction and directing reasonable use of immunological inhibitor clinically.
Description
Technical field:
The present invention relates to the method for the t cell surface antigen peptide of a kind of screening human histocompatibility antigen (HLA), and the application in preparation MHC-antigen peptide polymer, field of biological pharmacy belonged to.
Background technology:
Homologue, organ transplantation are a kind of important treatment technologies of medical field, are widely used.A large amount of patients' life has successfully been saved in the homotransplantation of kidney, heart, liver, marrow.More complicated and practical homotransplantation (many internal organs, pancreatic islets transplantation etc.) is also in research is used.The major cause of homotransplantation failure is because host T cell is attacked transplanting to produce, and causes graft to be ostracised.The major antigen of knowing the T cell recognition already is the HLA antigen on the graft, comprises I class and II class antigen.Suitable mutually tissue matching reduces the valid approach of transplant rejection between graft and host.Yet because it is very low to find HLA to join the chance that type is consistent fully, the HLA that most organ transplantation is adopted joins the half-matched of type or the organ that is not harmonious.The host then is suppressed by giving effective immunosuppressor for the rejection of graft.Thereby the organ transplantation patient will use immunosuppressor all the life, and because the danger that the non-specific immunity that immunosuppressor produces infringement produces complication to the patient.Reduce patients ' life quality, also cause the very big economical load of patient simultaneously.More complicated is: when clinical adverse appears in the patient, be difficult to judge that sometimes this reaction is because host's immunological rejection causes, or the murder by poisoning of immunosuppressor causes.And the clinical solution of these two kinds of harm just in time is conflicting: promptly will strengthen the immunosuppressor consumption when rejection occurring, and the consumption of immunosuppressor occur will reducing when immunosuppressor is damaged.Thereby it is very important and practical inventing first aid, the individual medication guide that a kind of technology that can accurately differentiate above-mentioned 2 kinds of clinical adverse causes of disease produces the patient who transplants for histoorgan.Can be used as the target cell of this detection for the specific T cell of graft: when this cell rising, rejection may appear in prompting.And the clinical toxicity that occurs under the situation of this vanished cell reaction is likely that immunosuppressor is excessive and causes.By detecting this class T cell, can carry out differential diagnosis effectively, instruct clinical use reasonable plan, also can instruct simultaneously its long-term reasonably medication according to each patient's individual difference, thereby can under the prerequisite that guarantees the graft long-term surviving, improve patients ' life quality, lower economical load.
Can use MHC-peptide multimer technology for detection specific T-cells at present, and can be with its sorting, activation, amplification.Not only can be the clinical foundation that diagnosis is provided, and can utilize these T cells to carry out biotherapy (strengthening or the inhibition immune response).The preparation of MHC-peptide multimer, key points of application are to adopt corresponding T cell recognition epitope peptide, and the size of these peptides is generally at 9-15 amino-acid residue.Yet, though know that up to the present the HLA antigen on the graft is the main identifying object of T cell.Have only that seldom HLA epi-position is resolved comes out, and be used for detection specificity T cell.Because HLA has the polymorphism of height, it is very difficult screening corresponding epitope peptide according to existing t cell epitope triage techniques again.The present invention is that another efficient screening t cell epitope peptide is used for MHC-peptide multimer screening system invention basis at us, adopt T2 like cell-display technique of bacteriophage screening-the HLA antigen peptide of group host T cell recognition.This group peptide can be used for preparing the MHC-peptide multimer.A kind of efficiently, special thereby develop, the method for detection, sorting, activation, the anti-homotransplant T of amplification host specificity cell is used for the detection of homograft rejecting reaction and immunosuppressor individualized treatment.
Summary of the invention:
The experimental procedure of existing screening human histocompatibility antigen peptide is complicated, and will synthesize a large amount of human histocompatibility antigen's peptide sections, and cost is very high.
The purpose of this invention is to provide a kind of method of screening human histocompatibility antigen's peptide.
Another object of the present invention provides the application that the human histocompatibility antigen's peptide with the screening of this system prepares the MHC-peptide multimer.
That utilizes that method of the present invention can be quick and a large amount of screens purpose peptide section.
A kind of efficient screening T cell antigen epitope peptide of the present invention prepares the method for MHC-peptide multimer (MHC tetramer), and its step is as follows:
(1) T2 like cell system different HLA antigens (comprising I class and II class antigen), that the endogenous antigen peptide offers to express defective is expressed in the preparation of iRNA technology;
(2) the preparation people mainly reaches the peptide chain gene pool of minor histocompatibility antigen;
(3) gene pool that utilizes step (2) to prepare, preparation phage display peptide display system;
(4) the T2 like cell system of step (1) preparation is mixed with the phage of step (3) preparation;
(5) uncombined phage is removed in washing;
(6) utilize phage-resistance capsid protein antibody test phage bonded situation and condition;
(7) carry out gradient elution with elutriant and remove the not high phage of affinity;
(8) adding phage-sensitive host e. coli makes the phage-infect intestinal bacteria on the T2 like cell, and is increased;
(9) by further separating the phage plasmid in the intestinal bacteria, and to wherein cDNA cloning and sequencing, filter out and MHC molecule bonded peptide section sequence;
(10) synthetic peptide section of being screened is bonded to the T2 like cell with this cytositimulation t cell responses, confirms peptide section t cell epitope activity.
Specific embodiment:
Embodiment 1: preparation endogenous antibody peptide is expressed the T2 like cell system of defective
The TAP gene of preparation T2 cell, the RNAi test kit of use Benitec company according to the step of product description of test, is prepared the T2 like cell of TAP genetic flaw.
The fragmentation of above-mentioned T2 like cell, extract the gene of T2 like cell according to the method for " molecular cloning ", increase with TAP promotor and terminator with round pcr again, carry out gel electrophoresis again, discovery does not have the TAP genonema.
Embodiment 2: preparation human histocompatibility antigen peptide chain gene pool
The T cell is bred in the DMEM that contains 4.5g/L glucose and 15%FBS, uses the ordinary method isolation of RNA, and with test kit the RNA reverse transcription become cDNA (Indianapolis, Ind).The cDNA that the first step prepares increases with PCR method again.
The DNA for preparing is carried out enzyme simultaneously with enzyme XhoI and SpeI cut, and gene is inserted into (production of Dyax company) in the phage display system.Obtain containing the phage system of various peptide sections.
Embodiment 3: the high phage of screening affinity
Use the PBS washed cell, there not being bonded phage flush away, increase the ionic strength of washings again, continue washing, in conjunction with untight phage flush away, constantly increase the ionic strength of washings, constantly wash removal, filter out at last and the high phage of T2 like cell avidity in conjunction with untight phage.
Embodiment 4: the amplification screen with the high phage of T2 like cell avidity
Adding phage-sensitive host e. coli makes the phage-infect intestinal bacteria on the T2 like cell, add the LB substratum, cultivated 24-48 hour down for 37 ℃, collect intestinal bacteria, by further separating the phage plasmid in the intestinal bacteria, and to wherein cDNA cloning and sequencing, filter out and MHC molecule bonded peptide section sequence, be YIGEVLVSV, SPSVDKARAEL, SPAVDKAQAEL.
Embodiment 5: with the synthetic MHC-peptide antibody polymer of human histocompatibility antigen's peptide section
Water-bath or freezing incubator precooling 1L fold damping fluid (being loaded in the beaker of 1L of stirrer), add reduced form paddy Guang acid anhydride peptide to 5mM at folding damping fluid, and oxidized form paddy Guang acid anhydride peptide is to 0.5mM, PMSF to 0.2mM.Calculate the necessary amounts that adds 1uM heavy chain, 2uM light chain and 30mg/L peptide, heavy chain and light chain are added in the 5ml injection damping fluid, in room temperature suction 5ml syringe.And in 500ul distilled water or DMSO, dilute human histocompatibility antigen's polypeptide according to human histocompatibility antigen's amino acid sequence of polypeptide (hydrophobicity).The resuspended damping fluid of 1L is put in high-speed stirring on the agitator (avoiding reaction solution to bubble), dropwise adds human histocompatibility antigen's polypeptide in the reaction solution that stirs with pipettor.Fiercely heavy chain and light chain are injected in the reaction solution of stirring in the position near stirrer as far as possible with No. 26 syringe needles.After adding light chain, it is slightly opaque that folding damping fluid should become.Deposit in 10 ℃, spend the night.With renaturation reactant ultrafiltration and concentration to 7ml.With Superdex75 gel-filtration purifying MHC-human histocompatibility antigen peptide list aggressiveness.Detect with SDS-PAGE, and identify its conformation with the ELISA method, one anti-be BB7.2.
The fluorescently-labeled yolk antibody of single aggressiveness of MHC-I and preparation is mixed in proportion, and 37 ℃ of temperature are bathed 1h, with Superdex200 gel-filtration purifying.FPLC detects.
The fluorescently-labeled monoclonal antibody of single aggressiveness of MHC-I and preparation is mixed in proportion, and 37 ℃ of temperature are bathed 1h, with Superdex200 gel-filtration purifying.FPLC detects.
The application clinically of embodiment 6:MHC-HLA-A2.1 peptide multimer
With above-mentioned MHC-HLA-A2.1 peptide tetramer or the polymer of preparing, and on the tetramer or polymer in conjunction with one the colour developing factor, this tetramer or polymer are mixed with tissue, organ transplantation patient's serum, separate and washing, flush away does not have bonded MHC-human histocompatibility antigen's peptide tetramer or polymer, with the quantity of cell counter detection T cell, learn that the concentration of T cell uprises, rejection may appear in prompting.Thereby can instruct clinical rational to use immunosuppressor.
The application clinically of embodiment 7:MHC-HLA-B7 peptide multimer
With above-mentioned MHC-HLA-B7 peptide tetramer or the polymer of preparing, and on the tetramer or polymer in conjunction with one the colour developing factor, this tetramer or polymer are mixed with tissue, organ transplantation patient's serum, separate and washing, flush away does not have bonded MHC-human histocompatibility antigen's peptide tetramer or polymer, with the quantity of cell counter detection T cell, learn that the concentration of T cell uprises, rejection may appear in prompting.Thereby can instruct clinical rational to use immunosuppressor.
Claims (7)
1. the method for t cell surface antigen peptide of a screening human histocompatibility antigen (HLA), it may further comprise the steps:
(1) expresses T2 like cell system different HLA antigens (comprising I class and II class antigen), that the endogenous antigen peptide offers to express defective with the preparation of iRNA technology;
(2) the preparation people mainly reaches the peptide chain gene pool of minor histocompatibility antigen;
(3) gene pool that utilizes step (2) to prepare, preparation phage display peptide display system;
(4) the T2 like cell system of step (1) preparation is mixed with the phage of step (3) preparation;
(5) uncombined phage is removed in washing;
(6) utilize phage-resistance capsid protein antibody test phage bonded situation and condition;
(7) carry out gradient elution with elutriant and remove the not high phage of affinity;
(8) adding phage-sensitive host e. coli makes the phage-infect intestinal bacteria on the T2 like cell, and is increased;
(9) by further separating the phage plasmid in the intestinal bacteria, and to wherein cDNA cloning and sequencing, filter out and MHC molecule bonded peptide section sequence;
(10) synthetic peptide section of being screened is bonded to the T2 like cell with this cytositimulation t cell responses, confirms peptide section t cell epitope activity.
2. the described a kind of efficient screening T cell antigen epitope peptide of claim 1 prepares the method for MHC-peptide multimer, and the described elutriant of its step (7) is the positively charged ion eluent.
3. the method for the t cell surface antigen peptide of claim 1 described a kind of screening human histocompatibility antigen (HLA), the peptide chain that obtains exists on people HLA I class and the I quasi-molecule, can be by the T cell antigen epitope peptide of TXi Baoshouti (TCR) identification.
4. the method for the t cell surface antigen peptide of a kind of screening human histocompatibility antigen as claimed in claim 3 (HLA), described can be HLA-A2.1 by the T cell antigen epitope peptide of TXi Baoshouti (TCR) identification, sequence is YIGEVLVSV.
5. the method for the t cell surface antigen peptide of a kind of screening human histocompatibility antigen as claimed in claim 3 (HLA), described can be HLA-B7 by the T cell antigen epitope peptide of TXi Baoshouti (TCR) identification, sequence is SPSVDKARAEL.
6. the method for the t cell surface antigen peptide of a kind of screening human histocompatibility antigen as claimed in claim 3 (HLA), described can be SPAVDKAQAEL by the T cell antigen epitope peptide sequence of TXi Baoshouti (TCR) identification.
7. the T cell antigen epitope peptide on the HLA antigen in the claim 4,5 or 6 is used to prepare the MHC tetramer or polymer, and be used for that tool repels the T cell of transplanted tissue of institute, organ dysfunction in the specific detection homologue, organ transplantation patient body, thereby can be used for detecting homograft rejection, and guide clinical rational to use immunosuppressor.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA021599742A CN1511958A (en) | 2002-12-31 | 2002-12-31 | System of T cell surface antigen peptide screening human tissue compatibility antigen (HLA) and its application in producing MHC-antigen peptide polymer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA021599742A CN1511958A (en) | 2002-12-31 | 2002-12-31 | System of T cell surface antigen peptide screening human tissue compatibility antigen (HLA) and its application in producing MHC-antigen peptide polymer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1511958A true CN1511958A (en) | 2004-07-14 |
Family
ID=34237703
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA021599742A Pending CN1511958A (en) | 2002-12-31 | 2002-12-31 | System of T cell surface antigen peptide screening human tissue compatibility antigen (HLA) and its application in producing MHC-antigen peptide polymer |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1511958A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101696974B (en) * | 2009-09-29 | 2013-03-06 | 才新 | HLA antibody specificity detecting method, cell dish and reagent kit |
| CN105358984A (en) * | 2013-03-15 | 2016-02-24 | 普罗格诺西斯生物科学公司 | Methods for detecting peptide/MHC/TCR binding |
| CN112110995A (en) * | 2019-06-19 | 2020-12-22 | 上海交通大学医学院 | Tumor neoantigen polypeptide and application thereof |
| CN112279911A (en) * | 2007-01-30 | 2021-01-29 | 埃皮瓦克斯公司 | Regulatory T cell epitopes, compositions and uses thereof |
-
2002
- 2002-12-31 CN CNA021599742A patent/CN1511958A/en active Pending
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112279911A (en) * | 2007-01-30 | 2021-01-29 | 埃皮瓦克斯公司 | Regulatory T cell epitopes, compositions and uses thereof |
| CN101696974B (en) * | 2009-09-29 | 2013-03-06 | 才新 | HLA antibody specificity detecting method, cell dish and reagent kit |
| CN105358984A (en) * | 2013-03-15 | 2016-02-24 | 普罗格诺西斯生物科学公司 | Methods for detecting peptide/MHC/TCR binding |
| CN112110995A (en) * | 2019-06-19 | 2020-12-22 | 上海交通大学医学院 | Tumor neoantigen polypeptide and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2008209176B2 (en) | Method for assaying antibodies in body fluids by immune reaction with glycoprotein 2 (GP2) from zymogenic granules of the pancreas for the differential diagnosis of inflammatory intestinal diseases and chronic pancreatitis | |
| US10071133B2 (en) | Method for destroying exosomes, kit for destroying exosomes, and method for isolating exosomes derived from normal cells | |
| CN116059194B (en) | Application of parahydroxybenzoic acid in preparation of protein amyloid fibrosis inhibitor | |
| CN108300688A (en) | Primary hepatocyte detaches and cultural method | |
| WO2016169239A1 (en) | 5 peptide related with integrin receptor αvβ3 | |
| CN1511958A (en) | System of T cell surface antigen peptide screening human tissue compatibility antigen (HLA) and its application in producing MHC-antigen peptide polymer | |
| CN118562720A (en) | Composition and culture medium for growing liver organoids and method for culturing fatty liver organoids | |
| JP2025515509A (en) | Refined mucus | |
| JP3442383B2 (en) | Synthetic peptides that enhance cell binding | |
| Jurd et al. | Surface immunoglobulins on Xenopus laevis lymphocytes | |
| Kenngott et al. | Identification of targeting peptides for mucosal delivery in sheep and mice | |
| CN119170106A (en) | A method for screening and preparing antioxidant peptides derived from horse milk whey protein and its application | |
| CN114478706B (en) | Polypeptide for three-dimensional culture of fiber network structure and application thereof | |
| JP7142310B2 (en) | Chimeric protein containing fibrinogen fragment and laminin fragment and its use | |
| CN101469016B (en) | Trichosanthin protein derived peptide and use thereof | |
| CN113667638A (en) | Functionalized red blood cell based on surface modification, preparation method thereof and application thereof in exosome separation | |
| CN103724409B (en) | Trichosanthin effective epitope peptide fragment with immunosuppression effect and application thereof | |
| CN114315965A (en) | Anti-obesity peptides and uses thereof | |
| GB2354241A (en) | Regulatory/unfolding peptides of ezrin | |
| JP3972108B2 (en) | Peptides for cell death induction | |
| RU2829120C1 (en) | METHOD OF PRODUCING NANODISCS CONTAINING A β1-ADRENORECEPTOR IN A NATIVE CONFORMATION | |
| JPH03198782A (en) | Carrier for gene introduction, complex of the carrier and gene, and method for gene introduction into cells | |
| RU2270021C2 (en) | Method for obtaining transfer-factor in cattle | |
| CN120905233A (en) | Coding sequence of recombinant protein, recombinant protein-liposome nanoparticle, preparation method and application | |
| EP2156844A1 (en) | AGENT EXHIBITING PROPERTIES TO FORM THE CELLULAR IMMUNITY AGAINST MYCOBACTERIUM TUBERCULOSIS H37 Rv, METHOD FOR THE PRODUCTION THEREOF (VARIANTS), A RECOMBINANT STRAIN AND AN AGENT FOR TUBERCULOSIS DIAGNOSIS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |